[5-alpha-reductase inhibitors in benign prostatic hyperplasia].
Sixteen patients presenting benign prostate gland hyperplasia undergo conservative treatment with Finasterid over the period 1992 through 1995. Prior to treatment, in all patients the subjective complaints are assayed on the basis of the IPSS rating system for severity of complaints. Uroflowmetry along with evaluating the quantity of residual urine using an isotope method, and echographic determination of the prostate gland volume, are performed. During the six- to nine-month follow-up study, an increase in maximal urinary output by 3.2 ml/sec, as well as reduction of the prostate gland volume by 24.5 per cent are documented in 78 per cent of the patients against the background of alleviated subjective complaints in 69 per cent.
Panchev
P
P
Neĭkov
K
K
D058891:5-alpha Reductase Inhibitors; D000368:Aged; D004341:Drug Evaluation; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects
D058891:5-alpha Reductase Inhibitors; D004791:Enzyme Inhibitors; D018120:Finasteride